Endothelial progenitor cells: Potential novel therapeutics for ischaemic stroke
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Stroke is classified into two main groups depending on its aetiology; ischaemic stroke and haemorrhagic stroke which successively develop from the occlusion or rupture of an artery leading to the brain. Despite being the leading cause of human cerebral damage, there is currently no medical therapy for haemorrhagic stroke and thrombolysis with recombinant tissue plasminogen activator remains the only approved pharmacotherapy for ischaemic stroke. However, due to its short therapeutic window (first 4.5 h of stroke onset) and increased risk of haemorrhage beyond this point, globally each year less than 1% of patients receive this therapy. Since, endothelial dysfunction, associated with inflammation and vascular permeability, remains the key early event in the pathogenesis of stroke, endogenous element(s) capable of countering this defect may help maintain vascular homeostasis and explain the overt differences observed in patients' functional outcome. Accumulating evidence indicate that bone marrow-derived endothelial progenitor cells (EPCs) equipped with an inherent capacity to repair endothelial damage and differentiate into few other cell lines represent one such element. Indeed, EPC-based cell therapy, backed by rigorous preclinical, translational and early proof-of-concept, safety and feasibility clinical studies, is now considered as an important novel therapeutic approach. However, several questions relating to optimal cell dosage, delivery route and immediate and sufficient availability of cells remain to be addressed before its efficacious translation to clinical practice. In this context, ex vivo expansion of EPCs leading to an abundant generation of functional outgrowth endothelial cells offers a great opportunity to address these issues and create a novel off-the-shelf type of therapeutic product.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke
Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Dávalos, A., Guidetti, D., Larrue, V., Lees, K. R., Medeghri, Z., Machnig, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804656 · Cited by 6,684 · cited 1×
“5 h of stroke onset) and markedly enhanced risk of haemorrhage beyond this point, globally less than 1% of patients receive this therapy each year [11].”
BackgroundClassification and natural history of clinically identifiable subtypes of cerebral infarction
Bamford, J., Sandercock, P., Dennis, M., Warlow, C., & Burn, J. (1991) · The Lancet · doi:10.1016/0140-6736(91)93206-o · Cited by 3,294
Circulating endothelial progenitor cells and cardiovascular outcomes
Werner, N., Kosiol, S., Schiegl, T., Ahlers, P., Walenta, K., Link, A., Böhm, M., & Nickenig, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043814 · Cited by 2,048
Chemokine signaling via the CXCR2 receptor reinforces senescence
Acosta, J. C., O'Loghlen, A., Banito, A., Guijarro, M. V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, M., Brown, C., Popov, N., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.038 · Cited by 1,801
Brain ischemia and reperfusion: molecular mechanisms of neuronal injury
White, B. C., Sullivan, J. M., DeGracia, D. J., O’Neil, B. J., Neumar, R. W., Grossman, L. I., Rafols, J. A., & Krause, G. S. (2000) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(00)00386-5 · Cited by 796
Kurz, D. J., Decary, S., Hong, Y., Trivier, E., Akhmedov, A., & Erusalimsky, J. D. (2004) · Journal of Cell Science · doi:10.1242/jcs.01097 · Cited by 499
Hermann, D. M., & Chopp, M. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70039-x · Cited by 333
Prasad, K., Sharma, A., Garg, A., Mohanty, S., Bhatnagar, S., Johri, S., Singh, K. K., Nair, V., Sarkar, R. S., Gorthi, S. P., et al. (2014) · Stroke · doi:10.1161/strokeaha.114.007028 · Cited by 307
Furumoto, K., Inoue, E., Nagao, N., Hiyama, E., & Miwa, N. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00351-8 · Cited by 240
Vascular disruption and blood–brain barrier dysfunction in intracerebral hemorrhage
Keep, R. F., Zhou, N., Xiang, J., Andjelkovic, A. V., Hua, Y., & Xi, G. (2014) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-11-18 · Cited by 220
Cited by
Vascular Ageing: Mechanisms, Risk Factors, and Treatment Strategies
Ya, J., & Bayraktutan, U. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411538 · Cited by 57
Self-citationReskiawan A. Kadir, R., Alwjwaj, M., Ahmad Othman, O., Rakkar, K., Sprigg, N., Bath, P. M., & Bayraktutan, U. (2022) · Brain Research · doi:10.1016/j.brainres.2022.147925 · Cited by 22
Self-citationKadir, R. R. A., Alwjwaj, M., & Bayraktutan, U. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01041-1 · Cited by 17
“1 3 directly differentiating into cerebral endothelial cells, and releasing wide range of paracrine factors to further potentiate neuro-angiogenesis (Bayraktutan 2019; Alwjwaj et al. 2021).”
BackgroundSelf-citation
Metadata
- Authors
- Bayraktutan, U.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 144
- Pages
- 181-191
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2938786634
- Cited by
- 82
- References
- 12
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endothelial progenitor cells: Potential novel therapeutics for ischaemic stroke. https://app.cochat.ai/papers/10.1016/j.phrs.2019.04.017
- The paper
- Bayraktutan, U. (2019). Endothelial progenitor cells: Potential novel therapeutics for ischaemic stroke. Pharmacological Research. https://doi.org/10.1016/j.phrs.2019.04.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.